Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma

被引：20

作者：

Gebhart, J. ^{[1
,2
]}

Lechner, K. ^{[1
,2
]}

Skrabs, C. ^{[1
,2
]}

Sliwa, T. ^{[3
]}

Muelduer, E. ^{[4
]}

Ludwig, H. ^{[4
]}

Noesslinger, T. ^{[5
,6
]}

Vanura, K. ^{[1
,2
]}

Stamatopoulos, K. ^{[7
]}

Simonitsch-Klupp, I. ^{[8
]}

Chott, A. ^{[9
]}

Quehenberger, P. ^{[10
]}

Mitterbauer-Hohendanner, G. ^{[10
]}

Pabinger, I. ^{[1
,2
]}

Jaeger, U. ^{[1
,2
]}

Geissler, K. ^{[3
]}

机构：

[1] Med Univ Vienna, Dept Med 1, Clin Div Hematol & Hemostaseol, Vienna, Austria

[2] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria

[3] Krankenhaus Hietzing, Dept Med 5, A-1130 Vienna, Austria

[4] Wilhelminenspital Vienna, Dept Med 1, Vienna, Austria

[5] Hanusch Hosp, Med Dept Hematol & Oncol 3, Vienna, Austria

[6] Hanusch Hosp, Ludwig Boltzmann Inst Leukemia Res & Hematol, Vienna, Austria

[7] G Papanicolaou Hosp, Dept Hematol, Thessaloniki, Greece

[8] Med Univ Vienna, Inst Pathol, Vienna, Austria

[9] Wilhelminenspital Vienna, Inst Pathol, Vienna, Austria

[10] Med Univ Vienna, Inst Lab Med, Vienna, Austria

来源：

THROMBOSIS RESEARCH | 2014年 / 134卷 / 05期

关键词：

Splenic marginal zone lymphoma SMZL; Lupus anticoagulant; Antiphospholipid antibodies; Thrombosis; Splenectomy; ANTIPHOSPHOLIPID SYNDROME; CLINICAL CHARACTERISTICS; PROGNOSTIC-FACTORS; IMGT/V-QUEST; V-J; SPLENECTOMY; IMMUNOGLOBULIN; RISK; THROMBOEMBOLISM; RITUXIMAB;

D O I：

10.1016/j.thromres.2014.08.021

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Splenic marginal zone lymphoma (SMZL) is a rare low-malignant Non-Hodgkin lymphoma (NHL), in which immune mediated paraneoplastic phenomena such as autoimmune hemolytic anemia (AIHA), autoimmune thrombocytopenia (ITP) and C1 esterase inhibitor deficiency are relatively common. Materials and Methods: We performed a multicenter retrospective study in 70 patients on the prevalence and clinical features of antiphospholipid antibodies (aPLA) in SMZL. Results and Conclusions: Nine patients (13%) had the diagnosis of a lupus anticoagulant (LA). The occurrence of venous thromboembolic events was significantly higher in LA positive patients compared to LA negative patients (4/9 [44%] vs 5/61 [8%], p = 0.002), especially within 12 months after splenectomy (3/6 [50%] vs 2/28 [7%], p = 0.007). None of the patients with LA had a persistent complete remission of LA after splenectomy, but complete remission of LA was achieved in 2/2 patients after rituximab-bendamustine immuno-chemotherapy. In conclusion, our data show a relatively high prevalence of aPLA in SMZL and an increased risk of postsplenectomy thrombosis in these patients. The fact that rituximab-bendamustine was effective for eradicating LA may be considered as an argument for using immuno-chemotherapy as first line therapy in SMZL patients with LA. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：980 / 984

页数：5

共 25 条

[1] Treatment of Splenic Marginal Zone Lymphoma: Splenectomy Versus Rituximab [J].